MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

JAYDESS Drug Utilization Study in Sweden

Completed
Conditions
Contraception
Interventions
Drug: Levonorgestrel (Jaydess, Skyla, BAY86-5028)
First Posted Date
2015-01-29
Last Posted Date
2023-01-31
Lead Sponsor
Bayer
Target Recruit Count
10000
Registration Number
NCT02349815
Locations
🇸🇪

Many Locations, Multiple Locations, Sweden

Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases

First Posted Date
2015-01-28
Last Posted Date
2017-04-05
Lead Sponsor
Bayer
Target Recruit Count
26065
Registration Number
NCT02349399

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

Completed
Conditions
Colorectal Neoplasms
Interventions
Drug: Regorafenib (Stivarga, BAY73-4506)
First Posted Date
2015-01-27
Last Posted Date
2018-09-10
Lead Sponsor
Bayer
Target Recruit Count
25
Registration Number
NCT02347852
Locations
🇦🇹

Klinikum Kreuzschwestern Wels GmbH, Multiple Locations, Austria

Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia

Phase 1
Completed
Conditions
Leukemia
Interventions
Drug: Atuveciclib, BAY1143572
First Posted Date
2015-01-26
Last Posted Date
2018-06-25
Lead Sponsor
Bayer
Target Recruit Count
42
Registration Number
NCT02345382
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇩🇪

Medizinische Fakultät Carl Gustav Carus, Dresden, Sachsen, Germany

and more 4 locations

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Phase 1
Completed
Conditions
Lymphoma Non-Hodgkin
Interventions
Drug: Copanlisib (BAY80-6946)
First Posted Date
2015-01-21
Last Posted Date
2023-01-20
Lead Sponsor
Bayer
Target Recruit Count
25
Registration Number
NCT02342665

Sorafenib Drug Drug Interaction Study in Healthy Male Subjects

Phase 1
Completed
Conditions
Drug Interactions
Interventions
Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Levothyroxine
First Posted Date
2015-01-06
Last Posted Date
2015-10-12
Lead Sponsor
Bayer
Target Recruit Count
25
Registration Number
NCT02332031

A Drug Utilization Study of Radium-223 in Sweden

Completed
Conditions
Neoplasms
Interventions
Other: Radium-223 dichloride (Xofigo, BAY88-8223)
First Posted Date
2015-01-06
Last Posted Date
2018-01-23
Lead Sponsor
Bayer
Target Recruit Count
37
Registration Number
NCT02331303

Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Completed
Conditions
Wet Macular Degeneration
Interventions
Drug: Aflibercept (EYLEA, BAY-86-5321)
First Posted Date
2014-12-22
Last Posted Date
2018-07-02
Lead Sponsor
Bayer
Target Recruit Count
236
Registration Number
NCT02321241

2-cohort Study of Adult Patients With Severe Hemophilia A in Greece

Completed
Conditions
Hemophilia A
Interventions
Other: Survey
First Posted Date
2014-12-18
Last Posted Date
2018-06-20
Lead Sponsor
Bayer
Target Recruit Count
72
Registration Number
NCT02319070

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Phase 3
Terminated
Conditions
Stroke
Interventions
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Other: Rivaroxaban-Placebo
Other: Aspirin-Placebo
First Posted Date
2014-12-10
Last Posted Date
2019-01-09
Lead Sponsor
Bayer
Target Recruit Count
7213
Registration Number
NCT02313909
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy